Highlights

  • Shares gained 25% to A$0.015 on 9 November 2026, giving Cynata a Market Capitalisation of about A$5.05 million.
  • A fully underwritten entitlement offer at A$0.01 per share closed on 27 October, with Caravel Securities taking up the shortfall.
  • The board continues evaluating Options to realise value from the Cymerus platform and to obtain rights to new assets.
  • FY2027 cash burn was forecast at about A$2.3 million after June trial results led to sweeping cost cuts.

After a brutal year in which its shares lost more than 90%, a 25% jump to A$0.015 on 9 November 2026 marks a small turn for Cynata Therapeutics (ASX:CYP). The Melbourne-based cell therapy company has just completed a tightly structured capital raising and is working through a strategic review that will shape what comes next for its Cymerus stem cell Manufacturing platform.

Raise Completed With Underwriter Support

Cynata launched a fully underwritten, pro-rata renounceable entitlement offer on 8 October 2026, offering three new shares for every eight held at A$0.01, each three shares carrying one free option. The price represented a 9.1% discount to the 7 October closing price. The offer targeted about A$913,000 before costs.

Results released on 30 October showed eligible shareholders applied for roughly 23.5 million new shares, about 25.8% take-up, raising about A$235,150. Lead manager and underwriter Caravel Securities takes the remaining shortfall of about 67.8 million shares, which should bring total proceeds to about A$912,962. The options carry a A$0.02 exercise price, expire on 3 May 2029 and will not be quoted. New shares began trading on 4 November.

How the Funds Will Be Used

Proceeds are earmarked for professional adviser, director and consultant fees linked to the company’s strategic objectives, offer costs and working capital. Cynata also plans an unmarketable parcel sale Facility for holdings worth less than A$500, with details to be announced separately.

Background to the Strategic Review

The review follows disappointing clinical results in June 2026. The Phase 3 SCUlpTOR knee osteoarthritis trial missed both co-primary endpoints, with 51.7% of the active group reaching the pain threshold at 24 months against 48.1% for control. The Phase 2 graft versus host disease trial also showed no significant difference on its primary endpoint and was terminated early. Neither trial raised safety concerns.

On 6 July, Cynata made all employee roles redundant, including its chief executive, and moved to board-led management. It secured a A$600,000 Research and Development tax incentive loan, ended FY2026 with about A$0.9 million in cash and forecast FY2027 cash burn of about A$2.3 million, including termination and trial close-out costs.

Future Outlook

The board says it is assessing development pathways for Cymerus, a platform designed to manufacture mesenchymal stromal cells at commercial scale, along with broader strategic options such as realising value from the technology and acquiring rights to new assets. No transaction has been announced, and Cynata has said it will update shareholders as developments occur.